Skip to Main Content
Try STAT+ TODAY
Trending:
Health
STAT+
Biotech
First Opinion
The Readout

A Bluebird muddle & your take on a big migraine trial

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan March 22, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for March 22, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Experts debate: Are we playing with fire when we…
Experts debate: Are we playing with fire when we edit human genes?
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
How Biogen got Aduhelm approved, Sanofi’s future in mRNA,…
How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga

Recommended Stories